These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23975664)

  • 1. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Stenholm L; Stoehlmacher-Williams J; Al-Batran SE; Heussen N; Akin S; Pauligk C; Lehmann S; Senff T; Hofheinz RD; Ehninger G; Kramer M; Goekkurt E
    Ann Oncol; 2013 Oct; 24(10):2581-2588. PubMed ID: 23975664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.
    Wu C; Li M; Hu C; Duan H
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):335-41. PubMed ID: 24288122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Goekkurt E; Al-Batran SE; Mogck U; Pauligk C; Hartmann JT; Kramer M; Jaeger E; Ehninger G; Stoehlmacher J
    Ann Oncol; 2009 Mar; 20(3):481-5. PubMed ID: 19074750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Goekkurt E; Al-Batran SE; Hartmann JT; Mogck U; Schuch G; Kramer M; Jaeger E; Bokemeyer C; Ehninger G; Stoehlmacher J
    J Clin Oncol; 2009 Jun; 27(17):2863-73. PubMed ID: 19332728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between common genetic variants in pre-microRNAs and prognosis of advanced gastric cancer treated with chemotherapy.
    Tahara T; Okubo M; Shibata T; Kawamura T; Sumi K; Ishizuka T; Nagasaka M; Nakagawa Y; Arisawa T; Ohmiya N; Hirata I
    Anticancer Res; 2014 Sep; 34(9):5199-204. PubMed ID: 25202115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
    Lorenzen S; Thuss-Patience P; Al-Batran SE; Lordick F; Haller B; Schuster T; Pauligk C; Luley K; Bichev D; Schumacher G; Homann N
    Ann Oncol; 2013 Aug; 24(8):2068-73. PubMed ID: 23592699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.
    Yoon KA; Yoon H; Park S; Jang HJ; Zo JI; Lee HS; Lee JS
    J Thorac Cardiovasc Surg; 2012 Oct; 144(4):794-807. PubMed ID: 22818121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
    Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
    Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Thomaidis T; Maderer A; Al-Batran SE; Kany J; Pauligk C; Steinmetz K; Schad A; Hofheinz R; Schmalenberg H; Homann N; Galle PR; Moehler M
    BMC Cancer; 2014 Jul; 14():476. PubMed ID: 24981311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the miR-146a rs2910164 polymorphism with gastric cancer susceptibility and prognosis.
    Jiang J; Jia ZF; Cao DH; Wu YH; Sun ZW; Cao XY
    Future Oncol; 2016 Oct; 12(19):2215-26. PubMed ID: 27267319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX.
    Oh SY; Shin A; Kim SG; Hwang JA; Hong SH; Lee YS; Kwon HC
    Oncotarget; 2016 May; 7(21):31204-14. PubMed ID: 27144430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
    Kim YJ; Goh PG; Kim ES; Lee SY; Moon HS; Lee ES; Sung JK; Kim SH; Lee BS; Jeong HY
    Korean J Gastroenterol; 2011 Dec; 58(6):311-7. PubMed ID: 22198228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
    Rivera F; Massutí B; Salcedo M; Sastre J; Martínez Galán J; Valladares-Ayerbes M; Serrano R; García de Paredes ML; Manzano JL; Galán M; Alsina M; Yuste Izquierdo AL; López C; Díaz-Rubio E; Conde V; Reboredo M; Cano MT; Pachón V; Aranda E
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):319-24. PubMed ID: 25491381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
    Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
    PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
    Ji SH; Lim DH; Yi SY; Kim HS; Jun HJ; Kim KH; Chang MH; Park MJ; Uhm JE; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    BMC Cancer; 2009 Apr; 9():110. PubMed ID: 19358705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-196a2 rs11614913 T > C polymorphism and risk of esophageal cancer in a Chinese population.
    Wei J; Zheng L; Liu S; Yin J; Wang L; Wang X; Shi Y; Shao A; Tang W; Ding G; Liu C; Chen S; Gu H
    Hum Immunol; 2013 Sep; 74(9):1199-205. PubMed ID: 23792053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
    J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Kripp M; Al-Batran SE; Rosowski J; Pauligk C; Homann N; Hartmann JT; Moehler M; Hofheinz RD
    Gastric Cancer; 2014 Jan; 17(1):181-7. PubMed ID: 23455717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.